

A Push-Catch System That Enables Effective Detoxification

by Christopher Shade, PhD, and Carrie Decker, ND

References

1. Terzano C, et al. Air pollution ultrafine particles: toxicity beyond the lung. *Eur Rev Med Pharmacol Sci.* 2010 Oct;14(10):809-21.
2. Lelieveld J, et al. The contribution of outdoor air pollution sources to premature mortality on a global scale. *Nature.* 2015 Sep 17;525(7569):367-71.
3. Sorg TJ, Chen AS, Wang L. Arsenic species in drinking water wells in the USA with high arsenic concentrations. *Water Res.* 2014 Jan 1;48:156-69.
4. Villaneuva CM, et al. Assessing Exposure and Health Consequences of Chemicals in Drinking Water: Current State of Knowledge and Research Needs. *Environ Health Perspect.* 2014 Mar; 122(3): 213–221.
5. Thapa K, Pant BR. Pesticides in vegetable and food commodities: environment and public health concern. *J Nepal Health Res Counc.* 2014 Sep-Oct;12(28):208-10.
6. Verger PJ, Boobis AR. Global food supply. Reevaluate pesticides for food security and safety. *Science.* 2013 Aug 16;341(6147):717-8.
7. Zalko D, et al. Viable skin efficiently absorbs and metabolizes bisphenol A. *Chemosphere.* 2011 Jan;82(3):424-30.
8. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. *J Biol Chem.* 2009 May 15;284(20):13291-5.
9. Carocci A, et al. Mercury toxicity and neurodegenerative effects. *Rev Environ Contam Toxicol.* 2014;229:1-18.
10. Irigaray P, et al. Lifestyle-related factors and environmental agents causing cancer: an overview. *Biomed Pharmacother.* 2007 Dec;61(10):640-58.
11. Bhatnagar A, et al. Environmental cardiology: studying mechanistic links between pollution and heart disease. *Circ Res.* 2006 Sep 29;99(7):692-705.
12. Mendiola J, et al. Exposure to environmental toxins in males seeking infertility treatment: a case-controlled study. *Reprod Biomed Online.* 2008 Jun;16(6):842-50.
13. Diaz-Sanchez D, et al. Diesel fumes and the rising prevalence of atopy: an urban legend? *Curr Allergy Asthma Rep.* 2003 Mar;3(2):146-52.
14. Grant DM. Detoxification pathways in the liver. *J Inher Metab Dis.* 1991;14(4):421-30.
15. Zamek-Gliszczynski MJ, et al. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and GSH metabolites. *Eur J Pharm Sci.* 2006 Apr;27(5):447-86.
16. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. *Toxicol Appl Pharmacol.* 2005 May 1;204(3):216-37.
17. Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. *Trends Pharmacol Sci.* 2010 Jun;31(6):246-54.
18. Rushmore TH, Kong AN. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. *Curr Drug Metab.* 2002 Oct;3(5):481-90.
19. Catania VA, et al. Co-regulation of expression of phase II metabolizing enzymes and multidrug resistance-associated protein 2. *Ann Hepatol.* 2004 Jan-Mar;3(1):11-7.
20. Hilgendorf C, et al. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. *Drug Metab Dispos.* 2007 Aug;35(8):1333-40.
21. Doherty MM, Charman WN. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? *Clin Pharmacokinet.* 2002;41(4):235-53.
22. Berggren S, et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. *Mol Pharm.* 2007 Mar-Apr;4(2):252-7.
23. Petri S, Körner S, Kiaei M. Nrf2/ARE Signaling Pathway: Key Mediator in Oxidative Stress and Potential Therapeutic Target in ALS. *Neurol Res Int.* 2012;2012:878030.

24. Risom L, Møller P, Loft S. Oxidative stress-induced DNA damage by particulate air pollution. *Mutat Res.* 2005 Dec 30;592(1-2):119-37.
25. Simmons SO, Fan CY, Yeoman K, et al. NRF2 Oxidative Stress Induced by Heavy Metals is Cell Type Dependent. *Curr Chem Genomics.* 2011;5:1-12.
26. Bruni F, Polosa PL, Galadeta MN. Nuclear Respiratory Factor 2 Induces the Expression of Many but Not All Human Proteins Acting in Mitochondrial DNA Transcription and Replication. *J Biol Chem.* 2010 February 5; 285(6): 3939–3948.
27. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. *J Biol Chem.* 2009 May 15;284(20):13291-5.
28. Itoh K, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. *Biochem Biophys Res Commun.* 1997 Jul 18;236(2):313-22.
29. Harvey CJ, Thimmulappa RK, Singh A, et al. Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. *Free Radic Biol Med.* 2009 Feb 15;46(4):443-53.
30. Singh A, Rangasamy T, Thimmulappa RK, et al. Glutathione peroxidase 2, the major cigarette smoke-inducible isoform of GPX in lungs, is regulated by Nrf2. *Am J Respir Cell Mol Biol.* 2006 Dec;35(6):639-50.
31. Zhang H, et al. Nrf2-regulated phase II enzymes are induced by chronic ambient nanoparticle exposure in young mice with age-related impairments. *Free Radic Biol Med.* 2012 May 1;52(9):2038-46.
32. Limonciel A, Jennings P. A review of the evidence that ochratoxin A is an Nrf2 inhibitor: implications for nephrotoxicity and renal carcinogenicity. *Toxins (Basel).* 2014 Jan 20;6(1):371-9.
33. Hung SC, et al. Indoxyl Sulfate: A Novel Cardiovascular Risk Factor in Chronic Kidney Disease. *J Am Heart Assoc.* 2017 Feb 7;6(2).
34. Lan Z, Bi KS, Chen XH. Ligustrazine attenuates elevated levels of indoxyl sulfate, kidney injury molecule-1 and clusterin in rats exposed to cadmium. *Food Chem Toxicol.* 2014 Jan;63:62-8.
35. Bolati D, et al. Indoxyl sulfate, a uremic toxin, downregulates renal expression of Nrf2 through activation of NF-κB. *BMC Nephrol.* 2013 Mar 4;14:56.
36. Riddington DW, Venkatesh B, Boivin CM, et al. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. *JAMA.* 1996 Apr 3;275(13):1007-12.
37. Lindén SK, et al. Mucin dynamics in intestinal bacterial infection. *PLoS One.* 2008;3(12):e3952.
38. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. *J Allergy Clin Immunol.* 2009 Jul;124(1):3-20.
39. Vasiluk L, Pinto LJ, Moore MM. Oral bioavailability of glyphosate: studies using two intestinal cell lines. *Environ Toxicol Chem.* 2005 Jan;24(1):153-60.
40. Anton PM, et al. Chronic ingestion of a potential food contaminant induces gastrointestinal inflammation in rats: role of nitric oxide and mast cells. *Dig Dis Sci.* 2000 Sep;45(9):1842-9.
41. Claus SP, Guillou H, Ellero-Simatos S. The gut microbiota: a major player in the toxicity of environmental pollutants? *Biofilms & Microbiomes.* 2016 May 4.
42. Awad WA, Hess C, Hess M. Enteric Pathogens and Their Toxin-Induced Disruption of the Intestinal Barrier through Alteration of Tight Junctions in Chickens. *Toxins (Basel).* 2017 Feb 10;9(2).
43. Batah J, et al. Clostridium difficile flagella induce a pro-inflammatory response in intestinal epithelium of mice in cooperation with toxins. *Sci Rep.* 2017 Jun 12;7(1):3256
44. Vázquez M, et al. In vitro evaluation of inorganic mercury and methylmercury effects on the intestinal epithelium permeability. *Food Chem Toxicol.* 2014 Dec;74:349-59.
45. Nadeem A, et al. Acute glutathione depletion leads to enhancement of airway reactivity and inflammation via p38MAPK-iNOS pathway in allergic mice. *Int Immunopharmacol.* 2014 Sep;22(1):222-9.
46. Carbonell LF, et al. Depletion of liver glutathione potentiates the oxidative stress and decreases nitric oxide synthesis in a rat endotoxin shock model. *Crit Care Med.* 2000 Jun 1;28(6):2002-6.
47. Tang W, et al. Endotoxin downregulates hepatic expression of P-glycoprotein and MRP2 in 2-acetylaminofluorene-treated rats. *Mol Cell Biol Res Commun.* 2000 Aug;4(2):90-7.
48. Kalitsky-Szirtes J, et al. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. *Drug Metab Dispos.* 2004 Jan;32(1):20-7.

-
49. Rumbeiha WK, et al. Augmentation of mercury-induced nephrotoxicity by endotoxin in the mouse. *Toxicology*. 2000 Oct 26;151(1-3):103-16.
50. Kosters A, Karpen SJ. The role of inflammation in cholestasis: clinical and basic aspects. *Semin Liver Dis*. 2010 May;30(2):186-94.
51. Zhou H, Hylemon PB. Bile acids are nutrient signaling hormones. *Steroids*. 2014 Aug;86:62-8.
52. Watanabe M, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. *Nature*. 2006 Jan 26;439(7075):484-9.
53. Islam KB, et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. *Gastroenterology*. 2011 Nov;141(5):1773-81.
54. Hellström PM, Nilsson I, Svenberg T. Role of bile in regulation of gut motility. *J Intern Med*. 1995 Apr;237(4):395-402.
55. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. *Physiol Rev*. 2003;83:633-671.
56. Zinchuk VS, et al. Asynchronous expression and colocalization of Bsep and Mrp2 during development of rat liver. *Am J Physiol Gastrointest Liver Physiol*. 2002 Mar;282(3):G540-8.
57. Rizzo G, et al. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. *Curr Drug Targets Immune Endocr Metabol Disord*. 2005 Sep;5(3):289-303.
58. Xie W, et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. *Proc Natl Acad Sci U S A*. 2001 Mar 13;98(6):3375-80.
59. Makishima M, et al. Vitamin D receptor as an intestinal bile acid sensor. *Science*. 2002 May 17;296(5571):1313-6.
60. Guo GL, et al. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. *J Biol Chem*. 2003 Nov 14;278(46):45062-71.
61. Boyer JL. New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. *J Hepatol*. 2007 Mar;46(3):365-71.
62. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. *Physiol Rev*. 2003 Apr;83(2):633-71.
63. Stieger B, et al. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. *Gastroenterology*. 2000 Feb;118(2):422-30.
64. Milkiewicz P, et al. Antidepressant induced cholestasis: hepatocellular redistribution of multidrug resistant protein (MRP2). *Gut*. 2003 Feb;52(2):300-3.
65. Rodríguez-Garay EA. Cholestasis: human disease and experimental animal models. *Ann Hepatol*. 2003 Oct-Dec;2(4):150-8.
66. Whiting JF, et al. Tumor necrosis factor-alpha decreases hepatocyte bile salt uptake and mediates endotoxin-induced cholestasis. *Hepatology*. 1995 Oct;22(4 Pt 1):1273-8.
67. Copple BL, Jaeschke H, Klaassen CD. Oxidative stress and the pathogenesis of cholestasis. *Semin Liver Dis*. 2010 May;30(2):195-204.
68. Kosters A, Karpen SJ. The role of inflammation in cholestasis: clinical and basic aspects. *Semin Liver Dis*. 2010 May;30(2):186-94.
69. Yang H, et al. Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications. *Hepatology*. 2009 Jun;49(6):1982-91.
70. Dietrich CG, et al. Influence of biliary cirrhosis on the detoxification and elimination of a food derived carcinogen. *Gut*. 2004 Dec;53(12):1850-5.
71. Yang H, et al. Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications. *Hepatology*. 2009 Jun;49(6):1982-91.
72. Crocenzi FA, et al. Localization status of hepatocellular transporters in cholestasis. *Front Biosci (Landmark Ed)*. 2012 Jan 1;17:1201-18.
73. Crocenzi FA, et al. Estradiol-17beta-D-glucuronide induces endocytic internalization of Bsep in rats. *Am J Physiol Gastrointest Liver Physiol*. 2003 Aug;285(2):G449-59.

74. Zinchuk V, Zinchuk O, Okada T. Experimental LPS-induced cholestasis alters subcellular distribution and affects colocalization of Mrp2 and Bsep proteins: a quantitative colocalization study. *Microsc Res Tech*. 2005 Jun 1;67(2):65-70.
75. Zelcer N, et al. Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na⁺-dependent bile-acid transporter. *Biochem J*. 2003 Jan 1;369(Pt 1):23-30.
76. Donner MG, Keppler D. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. *Hepatology*. 2001 Aug;34(2):351-9.
77. Brandoni A, et al. Expression and function of renal and hepatic organic anion transporters in extrahepatic cholestasis. *World J Gastroenterol*. 2012 Nov 28;18(44):6387-97.
78. Zollner G, et al. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. *Mol Pharm*. 2006 May-Jun;3(3):231-51.
79. Lee J, et al. Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. *Gastroenterology*. 2001 Dec;121(6):1473-84.
80. Kramer HJ. Impaired renal function in obstructive jaundice: roles of the thromboxane and endothelin systems. *Nephron*. 1997;77(1):1-12.
81. Dietrich CG, et al. Consequences of bile duct obstruction on intestinal expression and function of multidrug resistance-associated protein 2. *Gastroenterology*. 2004 Apr;126(4):1044-53.
82. Hruz P, et al. Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis. *Gut*. 2006 Mar;55(3):395-402.
83. Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. *Clin Liver Dis*. 2012 May;16(2):331-46.
84. Newton JL, et al. Cognitive impairment in primary biliary cirrhosis: symptom impact and potential etiology. *Hepatology*. 2008 Aug;48(2):541-9.
85. Elliott C, et al. Functional impairment in alcoholic liver disease and non-alcoholic fatty liver disease is significant and persists over 3 years of follow-up. *Dig Dis Sci*. 2013 Aug;58(8):2383-91.
86. Kim YJ. [Interpretation of liver function tests]. *Korean J Gastroenterol*. 2008 Apr;51(4):219-24.
87. Hatoff DE, Hardison WG. Induced synthesis of alkaline phosphatase by bile acids in rat liver cell culture. *Gastroenterology*. 1979 Nov;77(5):1062-7.
88. Ellis G, Worthy E, Goldberg DM. Lack of value of serum gamma-glutamyl transferase in the diagnosis of hepatobiliary disease. *Clin Biochem*. 1979 Aug;12(4):142-5.
89. Hill PG, Sammons HG. An assessment of 5'-nucleotidase as a liver-function test. *Q J Med*. 1967 Oct;36(144):457-68.
90. Righetti A, Kaplan MM. Disparate responses of serum and hepatic alkaline phosphatase and 5' nucleotidase to bile duct obstruction in the rat. *Gastroenterology*. 1972 May;62(5):1034-9.
91. Heikkinen J, et al. Changes in serum bile acid concentrations during normal pregnancy, in patients with intrahepatic cholestasis of pregnancy and in pregnant women with itching. *Br J Obstet Gynaecol*. 1981 Mar;88(3):240-5.
92. Patrick L. Mercury toxicity and antioxidants: Part 1: role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity. *Altern Med Rev*. 2002 Dec;7(6):456-71.
93. Perricone C, et al. Glutathione: a key player in autoimmunity. *Autoimmun Rev*. 2009 Jul;8(8):697-701.
94. de Quay B, Malinvern R, Lauterburg BH. Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral N-acetylcysteine. *AIDS*. 1992 Aug;6(8):815-9.
95. Westerveld GJ, et al. Antioxidant levels in the nasal mucosa of patients with chronic sinusitis and healthy controls. *Arch Otolaryngol Head Neck Surg*. 1997 Feb;123(2):201-4.
96. Omata Y, et al. Decreased zinc availability affects glutathione metabolism in neuronal cells and in the developing brain. *Toxicol Sci*. 2013 May;133(1):90-100.
97. Exner R, et al. Therapeutic potential of glutathione. *Wiener Klinische Wochenschrift*. 2000 Jul;112(14):610-6.
98. Witschi A, et al. The systemic availability of oral glutathione. *Eur J Clin Pharmacol*. 1992;43(6):667-9.
99. Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. *Pharmacol Ther*. 2014 Feb;141(2):150-9.

-
100. Lu, S.C. Regulation of hepatic glutathione synthesis: current concepts and controversies. *FASEB J.* 1999; 13, 1169–1183
101. Gibson KR, et al. Evaluation of the antioxidant properties of N-acetylcysteine in human platelets: prerequisite for bioconversion to glutathione for antioxidant and antiplatelet activity. *J Cardiovasc Pharmacol.* 2009 Oct;54(4):319-26.
102. Vogel JU, et al. Effects of S-acetylglutathione in cell and animal model of herpes simplex virus type 1 infection. *Med Microbiol Immunol.* 2005 Jan;194(1-2):55-9.
103. Zeevalk GD, Bernard LP, Guilford FT. Liposomal-glutathione provides maintenance of intracellular glutathione and neuroprotection in mesencephalic neuronal cells. *Neurochem Res.* 2010 Oct;35(10):1575-87.
104. Okada K, et al. Nrf2 counteracts cholestatic liver injury via stimulation of hepatic defense systems. *Biochem Biophys Res Commun.* 2009 Nov 20;389(3):431-6.
105. Stewart D, et al. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. *J Biol Chem.* 2003 Jan 24;278(4):2396-402.
106. Itoh K, Tong KI, Yamamoto M. Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. *Free Radic Biol Med.* 2004 May 15;36(10):1208-13.
107. Suh JH, et al. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. *Proc Natl Acad Sci U S A.* 2004 Mar 9;101(10):3381-6.
108. Zhang C, et al. Selenium triggers Nrf2-mediated protection against cadmium-induced chicken hepatocyte autophagy and apoptosis. *Toxicol In Vitro.* 2017 Oct;44:349-356.
109. Zhao F, et al. Silymarin attenuates paraquat-induced lung injury via Nrf2-mediated pathway in vivo and in vitro. *Clin Exp Pharmacol Physiol.* 2015 Jul 14.
110. Surh YJ, Kundu JK, Na HK. Nrf2 as a master redox switch in turning on the cellular signalling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. *Planta Med.* 2008 Oct;74(13):1526-39.
111. Saw CL, et al. Pharmacodynamics of dietary phytochemical indoles I3C and DIM: Induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates. *Biopharm Drug Dispos.* 2011 Jul;32(5):289-300.
112. Laudenslager ML, et al. A randomized controlled pilot study of inflammatory gene expression in response to a stress management intervention for stem cell transplant caregivers. *J Behav Med.* 2016 Apr;39(2):346-54.
113. Tsou YH, et al. Treadmill exercise activates Nrf2 antioxidant system to protect the nigrostriatal dopaminergic neurons from MPP⁺ toxicity. *Exp Neurol.* 2015 Jan;263:50-62.
114. Li T, et al. Effects of different exercise durations on Keap1-Nrf2-ARE pathway activation in mouse skeletal muscle. *Free Radic Res.* 2015 Oct;49(10):1269-74.
115. Zollner G, et al. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. *J Hepatol.* 2003 Oct;39(4):480-8.
116. Yang H, et al. Induction of avian musculoaponeurotic fibrosarcoma proteins by toxic bile acid inhibits expression of glutathione synthetic enzymes and contributes to cholestatic liver injury in mice. *Hepatology.* 2010 Apr;51(4):1291-301.
117. Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. *Gut.* 2002 Mar;50(3):436-9.
118. Marschall HU, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. *Gastroenterology.* 2005 Aug;129(2):476-85.
119. Hişmioğulları AA, Bozdayı AM, Rahman K. Biliary lipid secretion. *Turk J Gastroenterol.* 2007 Jun;18(2):65-70.
120. Morita SY, Terada T. Molecular mechanisms for biliary phospholipid and drug efflux mediated by ABCB4 and bile salts. *Biomed Res Int.* 2014;2014:954781.
121. Chanussot F, Benkoël L. Prevention by dietary (n-6) polyunsaturated phosphatidylcholines of intrahepatic cholestasis induced by cyclosporine A in animals. *Life Sci.* 2003 Jun 13;73(4):381-92.
122. Karaman A, et al. Protective effect of polyunsaturated phosphatidylcholine on liver damage induced by biliary obstruction in rats. *J Pediatr Surg.* 2003 Sep;38(9):1341-7.

-
123. Canty DJ, Zeisel SH. Lecithin and choline in human health and disease. *Nutr Rev*. 1994 Oct;52(10):327-39.
124. Wallace TC, Fulgoni VL. Usual Choline Intakes Are Associated with Egg and Protein Food Consumption in the United States. *Nutrients*. 2017 Aug 5;9(8).
125. Zeisel SH. Gene response elements, genetic polymorphisms and epigenetics influence the human dietary requirement for choline. *IUBMB Life*. 2007 Jun;59(6):380-7.
126. Oztürk N, et al. Choleretic activity of Gentiana lutea ssp. symphyandra in rats. *Phytomedicine*. 1998 Aug;5(4):283-8.
127. Lian LH, et al. Gentiana manshurica Kitagawa reverses acute alcohol-induced liver steatosis through blocking sterol regulatory element-binding protein-1 maturation. *J Agric Food Chem*. 2010 Dec 22;58(24):13013-9.
128. Wang AY, et al. Gentiana manshurica Kitagawa prevents acetaminophen-induced acute hepatic injury in mice via inhibiting JNK/ERK MAPK pathway. *World J Gastroenterol*. 2010 Jan 21;16(3):384-91.
129. Schütz K, Carle R, Schieber A. Taraxacum--a review on its phytochemical and pharmacological profile. *J Ethnopharmacol*. 2006 Oct 11;107(3):313-23.
130. You Y, et al. In vitro and in vivo hepatoprotective effects of the aqueous extract from Taraxacum officinale (dandelion) root against alcohol-induced oxidative stress. *Food Chem Toxicol*. 2010 Jun;48(6):1632-7.
131. Dolara P, et al. Local anaesthetic, antibacterial and antifungal properties of sesquiterpenes from myrrh. *Planta Med*. 2000 May;66(4):356-8.
132. Sheir Z, et al. A safe, effective, herbal antischistosomal therapy derived from myrrh. *Am J Trop Med Hyg*. 2001 Dec;65(6):700-4.
133. Shen T, Li GH, Wang XN, Lou HX. The genus Commiphora: a review of its traditional uses, phytochemistry and pharmacology. *J Ethnopharmacol*. 2012 Jul 13;142(2):319-30.
134. Frawley D, Lad V. The Yoga of Herbs: An Ayurvedic Guide to Herbal Medicine. Lotus Press, 1986.
135. Shah R, Gulati V, Palombo EA. Pharmacological properties of guggulsterones, the major active components of gum guggul. *Phytotherapy Research*. 2012 Nov;26(11):1594-605.
136. Abenavoli L, et al. Milk thistle in liver diseases: past, present, future. *Phytother Res*. 2010 Oct;24(10):1423-32.
137. Crocenzi FA, Roma MG. Silymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication. *Curr Med Chem*. 2006;13(9):1055-74.
138. Crocenzi FA, et al. Silibinin prevents cholestasis-associated retrieval of the bile salt export pump, Bsep, in isolated rat hepatocyte couplets: possible involvement of cAMP. *Biochem Pharmacol*. 2005 Apr 1;69(7):1113-20.
139. Crocenzi FA, et al. Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: a study in vivo and in isolated hepatocyte couplets. *Hepatology*. 2001 Aug;34(2):329-39.
140. Gu M, et al. Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor. *Front Pharmacol*. 2016 Sep 28;7:345.
141. Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. *J Toxicol Clin Toxicol*. 1999;37(6):731-51.
142. Nolan JP, et al. Endotoxin binding by charged and uncharged resins. *Proc Soc Exp Biol Med*. 1975 Jul;149(3):766-70.
143. Du XN, et al. Effect of activated charcoal on endotoxin adsorption. Part I. An in vitro study. *Biomater Artif Cells Artif Organs*. 1987;15(1):229-35.
144. Pegues AS, et al. The removal of 14C labeled endotoxin by activated charcoal. *Int J Artif Organs*. 1979 May;2(3):153-8.
145. Zhelezova A, Cederlund H, Stenström J. Effect of Biochar Amendment and Ageing on Adsorption and Degradation of Two Herbicides. *Water Air Soil Pollut*. 2017;228(6):216.
146. Chiang YC, Chiang PC, Huang CP. Effects of pore structure and temperature on VOC adsorption on activated carbon. *Carbon*. 2001 Apr 30;39(4):523-34.

147. Monge Mdel P, et al. Activated carbons as potentially useful non-nutritive additives to prevent the effect of fumonisin B1 on sodium bentonite activity against chronic aflatoxicosis. *Food Addit Contam Part A Chem Anal Control Expo Risk Assess.* 2016 Jun;33(6):1043-5.
148. Schulman G. A nexus of progression of chronic kidney disease: tryptophan, profibrotic cytokines, and charcoal. *J Ren Nutr.* 2012 Jan;22(1):107-13.
149. de Souza JB, et al. Oral activated charcoal prevents experimental cerebral malaria in mice and in a randomized controlled clinical trial in man did not interfere with the pharmacokinetics of parenteral artesunate. *PLoS One.* 2010 Apr 15;5(4):e9867.
150. Tuomi T, et al. Mycotoxins in crude building materials from water-damaged buildings. *Appl Environ Microbiology.* 2000 May 1;66(5):1899-904.
151. Abdel-Wahhab MA, et al. Adsorption of sterigmatocystin by montmorillonite and inhibition of its genotoxicity in the Nile tilapia fish (*Oreochromis niloticus*). *Mutat Res.* 2005 Apr 4;582(1-2):20-7.
152. Abbès S, et al. Preventive role of phyllosilicate clay on the Immunological and Biochemical toxicity of zearalenone in Balb/c mice. *Int Immunopharmacol.* 2006 Aug;6(8):1251-8.
153. Mitchell NJ, et al. Calcium montmorillonite clay reduces AFB1 and FB1 biomarkers in rats exposed to single and co-exposures of aflatoxin and fumonisin. *J Appl Toxicol.* 2014 Jul;34(7):795-804.
154. Park Y, et al. Bisphenol A sorption by organo-montmorillonite: implications for the removal of organic contaminants from water. *Chemosphere.* 2014 Jul;107:249-56.
155. Lagaly G. Pesticide-clay interactions and formulations. *App Clay Sci.* 2001 May 31;18(5):205-9.
156. Park Y, et al. Removal of herbicides from aqueous solutions by modified forms of montmorillonite. *J Colloid Interface Sci.* 2014 Feb 1;415:127-32.
157. Sukenik A, et al. Removal of cyanobacteria and cyanotoxins from lake water by composites of bentonite with micelles of the cation octadecyltrimethyl ammonium (ODTMA). *Water Res.* 2017 Sep 1;120:165-173.
158. Naseem R, Tahir SS. Removal of Pb (II) from aqueous/acidic solutions by using bentonite as an adsorbent. *Water Res.* 2001 Nov 30;35(16):3982-6.
159. Pradas EG, et al. Adsorption of cadmium and zinc from aqueous solution on natural and activated bentonite. *J Chemical Tech Biotech.* 1994 Mar 1;59(3):289-95.
160. Vieira MG, et al. Sorption kinetics and equilibrium for the removal of nickel ions from aqueous phase on calcined Bofe bentonite clay. *J Haz Mat.* 2010 May 15;177(1):362-71.
161. Abbès S, et al. Inactivation of cadmium induced immunotoxicological alterations in rats by Tunisian montmorillonite clay. *Int Immunopharmacol.* 2007 Jun;7(6):750-60.
162. Mahrous KF, et al. Inhibition of cadmium- induced genotoxicity and histopathological changes in Nile tilapia fish by Egyptian and Tunisian montmorillonite clay. *Ecotoxicol Environ Saf.* 2015 Sep;119:140-7.
163. Haydel SE, Remeni CM, Willias LB. Broad-spectrum in vitro antibacterial activities of clay minerals against antibiotic-susceptible and antibiotic-resistant bacterial pathogens. *J Antimicrob Chemother* 2008 Feb; 61(2): 353-361.
164. Waibel KH, et al. Safety of chitosan bandages in shellfish allergic patients. *Mil Med.* 2011 Oct;176(10):1153-6.
165. Baldrick P. The safety of chitosan as a pharmaceutical excipient. *Regul Toxicol Pharmacol.* 2010;56:290-9.
166. Vahouny GV, et al. Comparative effects of chitosan and cholestyramine on lymphatic absorption of lipids in the rat. *Am J Clin Nutr.* 1983 Aug;38(2):278-84.
167. Gallaher CM, et al. Cholesterol reduction by glucomannan and chitosan is mediated by changes in cholesterol absorption and bile acid and fat excretion in rats. *J Nutr.* 2000 Nov;130(11):2753-9.
168. Al-Anati L, Petzinger E. Immunotoxic activity of ochratoxin A. *J Vet Pharmacol Ther.* 2006 Apr;29(2):79-90.
169. Polizzi V, et al. JEM Spotlight: Fungi, mycotoxins and microbial volatile organic compounds in mouldy interiors from water-damaged buildings. *J Enviro Monitor.* 2009;11(10):1849-58.
170. Bornet A, Teissedre PL. Chitosan, chitin-glucan and chitin effects on minerals (iron, lead, cadmium) and organic (ochratoxin A) contaminants in wines. *Euro Food Res Tech.* 2008 Feb 1;226(4):681-9.

171. Quintela S, et al. Ochratoxin A removal from red wine by several oenological fining agents: bentonite, egg albumin, allergen-free adsorbents, chitin and chitosan. *Food Addit Contam Part A Chem Anal Control Expo Risk Assess.* 2012;29(7):1168-74.
172. Gerente C, et al. Application of chitosan for the removal of metals from wastewaters by adsorption—mechanisms and models review. *Crit Rev Enviro Sci Tech.* 2007 Jan 1;37(1):41-127.
173. Shafaei A, Ashtiani FZ, Kaghazchi T. Equilibrium studies of the sorption of Hg (II) ions onto chitosan. *Chem Eng J.* 2007 Sep 15;133(1):311-6.
174. Salim CJ, Liu H, Kennedy JF. Comparative study of the adsorption on chitosan beads of phthalate esters and their degradation products. *Carbo Polymers.* 2010 Jul 7;81(3):640-4.
175. Dehghani MH, et al. Adsorptive removal of endocrine disrupting bisphenol A from aqueous solution using chitosan. *J Enviro Chem Eng* 2016 Sep 30;4(3):2647-55.
176. Davydova VN, et al. Interaction of bacterial endotoxins with chitosan. Effect of endotoxin structure, chitosan molecular mass, and ionic strength of the solution on the formation of the complex. *Biochemistry (Mosc).* 2000 Sep;65(9):1082-90.
177. Solov'eva T, et al. Marine compounds with therapeutic potential in gram-negative sepsis. *Mar Drugs.* 2013 Jun 19;11(6):2216-29.
178. Lee HW, et al. Chitosan oligosaccharides, dp 2-8, have prebiotic effect on the Bifidobacterium bifidum and Lactobacillus sp. *Anaerobe.* 2002 Dec;8(6):319-24.
179. Kong M, et al. Antimicrobial properties of chitosan and mode of action: a state of the art review. *Int J Food Microbiol.* 2010 Nov 15;144(1):51-63.
180. Saha B, et al. Sorption of trace heavy metals by thiol containing chelating resins. *Solv Extract Ion Exch.* 2000 Jan 1;18(1):133-67.
181. Sangvanich T, et al. Novel oral detoxification of mercury, cadmium, and lead with thiol-modified nanoporous silica. *ACS Appl Mater Interfaces.* 2014 Apr 23;6(8):5483-93.
182. Clarkson TW, et al. Tests of efficacy of antidotes for removal of methylmercury in human poisoning during the Iraq outbreak. *J Pharmacol Exp Ther.* 1981 Jul;218(1):74-83.
183. Rafati-Rahimzadeh M, et al. Current approaches of the management of mercury poisoning: need of the hour. *Daru.* 2014 Jun 2;22:46.
184. Clarkson TW, Small H, Norseth T. Excretion and Absorption of Methyl Mercury After Polythiol Resin Treatment. *Arch Enviro Health: Int J.* 1973 Apr 1;26(4):173-6.
185. Smith SW. The role of chelation in the treatment of other metal poisonings. *J Med Toxicol.* 2013 Dec;9(4):355-69.
186. Shade C. Liposomes as advanced delivery systems for nutraceuticals. *Integr Med.* 2016;15(1):33-36.
187. Kraft JC, et al. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. *J Pharm Sci.* 2014 Jan;103(1):29-52.
188. Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. *J Angiogenes Res.* 2010; 2:14.
189. Muthu MS, et al. Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. *Int J Pharm.* 2011 Dec 15;421(2):332-40.
190. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. *Adv Drug Deliv Rev.* 2013 Jan;65(1):36-48.
191. Ahn H, Park JH. Liposomal delivery systems for intestinal lymphatic drug transport. *Biomater Res.* 2016 Nov 23;20:36.
192. Laouini A, et al. Preparation, characterization, and applications of liposomes: State of the art. *J Colloid Sci Biotechnol.* 2012;1:147–168.
193. Bulbake U, et al. Liposomal Formulations in Clinical Use: An Updated Review. *Pharmaceutics.* 2017 Mar 27;9(2). pii: E12.
194. Yang Z, et al. Effect of liposomes on the absorption of water-soluble active pharmaceutical ingredients via oral administration. *Curr Pharm Des.* 2013;19(37):6647-54.
195. Paltsev M, et al. Comparative preclinical pharmacokinetics study of 3,3'-diindolylmethane formulations: is personalized treatment and targeted chemoprevention in the horizon? *EPMA J.* 2013 Dec 10;4(1):25.

-
196. Yang KY, et al. Silymarin-loaded solid nanoparticles provide excellent hepatic protection: physicochemical characterization and in vivo evaluation. *Int J Nanomedicine*. 2013;8:3333-43.
197. Zeevalk GD, Bernard LP, Guilford FT. Liposomal-glutathione provides maintenance of intracellular glutathione and neuroprotection in mesencephalic neuronal cells. *Neurochem Res*. 2010 Oct;35(10):1575-87.
198. Spector AA, Yorek MA. Membrane lipid composition and cellular function. *J Lipid Res*. 1985 Sep;26(9):1015-35.